Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC

NCT: NCT04585490 · RECRUITING

NCT IDNCT04585490
StatusRECRUITING
Start Date2021-08-25
SponsorStanford University (OTHER)
First posted
Last updated

Brief Summary

The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑